Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/46

Synopsis

Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension. Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.